BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 6365785)

  • 1. Binding of cryptococcal polysaccharide to Cryptococcus neoformans.
    Kozel TR; Hermerath CA
    Infect Immun; 1984 Mar; 43(3):879-86. PubMed ID: 6365785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-encapsulated variant of Cryptococcus neoformans. II. Surface receptors for cryptococcal polysaccharide and their role in inhibition of phagocytosis by polysaccharide.
    Kozel TR
    Infect Immun; 1977 Apr; 16(1):99-106. PubMed ID: 326680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opsonization of Cryptococcus neoformans by human immunoglobulin G: masking of immunoglobulin G by cryptococcal polysaccharide.
    McGaw TG; Kozel TR
    Infect Immun; 1979 Jul; 25(1):262-7. PubMed ID: 383615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opsonization of encapsulated Cryptococcus neoformans by specific anticapsular antibody.
    Kozel TR; Follette JL
    Infect Immun; 1981 Mar; 31(3):978-84. PubMed ID: 7014468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concomitant but not causal association between surface charge and inhibition of phagocytosis by cryptococcal polysaccharide.
    Kozel TR; Reiss E; Cherniak R
    Infect Immun; 1980 Aug; 29(2):295-300. PubMed ID: 7011970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The capsule of cryptococcus neoformans passively inhibits phagocytosis of the yeast by macrophages.
    Kozel TR; Gotschlich EC
    J Immunol; 1982 Oct; 129(4):1675-80. PubMed ID: 7050244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of purified and radioiodinated capsular polysaccharides from Cryptococcus neoformans serotype A strains to capsule-free mutants.
    Small JM; Mitchell TG
    Infect Immun; 1986 Dec; 54(3):742-50. PubMed ID: 3536747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.
    Small JM; Mitchell TG
    Infect Immun; 1989 Dec; 57(12):3751-6. PubMed ID: 2680980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phagocytosis by cryptococcal polysaccharide: dissociation of the attachment and ingestion phases of phagocytosis.
    Kozel TR; Mastroianni RP
    Infect Immun; 1976 Jul; 14(1):62-7. PubMed ID: 780279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phagocytosis of Cryptococcus neoformans by normal and thioglycolate-activated macrophages.
    Swenson FJ; Kozel TR
    Infect Immun; 1978 Sep; 21(3):714-20. PubMed ID: 361575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans.
    Laxalt KA; Kozel TR
    Infect Immun; 1979 Nov; 26(2):435-40. PubMed ID: 397927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation of a hydrophobic surface from phagocytosis of encapsulated and non-encapsulated cryptococcus neoformans.
    Kozel TR
    Infect Immun; 1983 Mar; 39(3):1214-9. PubMed ID: 6341232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the capsule in phagocytosis of Cryptococcus neoformans.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
    Young BJ; Kozel TR
    Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of Cryptococcus neoformans impairs antigen-specific T-cell responses.
    Collins HL; Bancroft GJ
    Infect Immun; 1991 Nov; 59(11):3883-8. PubMed ID: 1937747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide.
    Schlageter AM; Kozel TR
    Infect Immun; 1990 Jun; 58(6):1914-8. PubMed ID: 2187813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide.
    Eckert TF; Kozel TR
    Infect Immun; 1987 Aug; 55(8):1895-9. PubMed ID: 2440810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular fate of Cryptococcus neoformans.
    Tacker JR; Farhi F; Bulmer GS
    Infect Immun; 1972 Aug; 6(2):162-7. PubMed ID: 4569916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Infect Immun; 1988 Nov; 56(11):2794-800. PubMed ID: 3049374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.